ProMetic Life Sciences Inc. (PLI) 2009年年度报告「TSX」.pdf

1、 Life Sciences Inc.2009 Annual ReportPathogen Removal from BloodExtraction&Recovery of Plasma-derived Therapeutic ProteinsTherapeutics to Treat Anemia&Other DiseasesTherapeuticsto Treat Rare Bleeding DisordersFront Cover Illustration These stylized red blood cells in a DNA configuration represent th

2、e Companys diverse activities related to blood as well as ProMetics fundamental business strategy that first-in-class therapeutics for unmet medical needs and best-in-class medications that offer superior treatment options for patients will continue to be key value drivers for the Company.Significan

3、t EvEntS2009 AND SubSequeNT To yeAR eNDMessage to Shareholders 4ProMetics Technologies 8MD&A 17Consolidated Financial Statements 39ProMetic collaboration with HemCon Medical Technologies,Inc.moved to a second phase following successful completion of the first phase of the development of a single-use

4、 antibody capture device for the removal of isoagglutinin antibodies from human plasma.ProMetic finalized an equity investment of$3 M US and a five year loan of$10 M US with Abraxis BioScience,Inc.Novozymes and ProMetic entered into a strategic alliance regarding proprietary albumin purification tec

5、hnology based upon a synthetic-ligand affinity adsorbent developed by ProMetics uK subsidiary,ProMetic BioSciences Ltd.The new synthetic-ligand affinity adsorbent,AlbuPure,will be co-marketed by both companies.ProMetic entered into a collaboration agreement with Abraxis BioScience,Inc.to develop and

6、 commercialize various applications deriving from ProMetics prion capture technology platform.FDA guidance and recommendations corroborated ProMetics strategy for the development of PBI-1402 and its analogues for the treatment of anemia in cancer patients and in patients with chronic kidney disease.